Company Overview
Snapshot
Founded in October 2019 by Yaron Shoob, Elixie operates with 1–10 employees. The company has secured $2 million in total capital across one funding round and holds one patent. Elixie is actively engaged in clinical trials for its cannabinoid products.
Business overview
Elixie is a clinical-stage biotech company focused on enhancing cannabinoids for the symptomatic relief of neurological disorders. The company utilizes NANOLIX, a patented and clinically proven Self-nano emulsifying drug delivery system (SNEDDS), to encapsulate validated active pharmaceutical ingredients (APIs). By targeting orphan diseases, Elixie aims to register pharmaceuticals through an accelerated market entry strategy with reduced risks. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, Medical Cannabis, and Drug Delivery, serving B2B2C and B2B business models across geomarkets including the United Kingdom, Australia, Canada, United States, Israel, Europe, and the Americas.
Log in to access full profile ›Company Intelligence Q&A
- What is Elixie's primary focus?
- Elixie is a clinical-stage biotech company focused on enhancing cannabinoids for the symptomatic relief of neurological disorders, utilizing its patented NANOLIX drug delivery system.
- When was Elixie founded?
- Elixie was founded in October 2019.
- Who is a key founder of Elixie?
- Yaron Shoob is a co-founder and CEO of Elixie.
- What is Elixie's total capital raised?
- Elixie has raised $2 million in total capital.
- What is the primary technology used by Elixie?
- Elixie uses NANOLIX, a patented and clinically proven Self-nano emulsifying drug delivery system (SNEDDS), to encapsulate active pharmaceutical ingredients.